Controlled human infection model trials for hepatitis C virus represent an important
opportunity to identify correlates of protective immunity against a well-characterized …

The design of a clinical trial for a controlled human infection model (CHIM) to accelerate
hepatitis C virus (HCV) vaccine development requires careful consideration. The design of a …

Despite the existence of established treatments for hepatitis C virus (HCV), more effective
means of preventing infection, such as a vaccine, are arguably needed to help reduce …

Unless urgently needed to prevent a pandemic, the development of a viral vaccine should
follow a rigorous scientific approach. Each vaccine candidate should be designed …

Hepatitis C virus (HCV) elimination has been a goal of the public health and scientific
communities since its identification in 1989. Despite the advance and availability of highly …

Hepatitis C virus (HCV) infects more than 170 million people globally and is a leading cause
of liver cirrhosis, transplantation and hepatocellular carcinoma. Current gold-standard …

For any controlled human infection model (CHIM), a safe, standardized, and biologically
relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose …

Despite difficulties associated with extreme variability and mutability of hepatitis C virus
(HCV), several vaccines that prevent initial infection or viral persistence, or that clear …

Hepatitis C virus (HCV) remains a major global health concern. Directly acting antiviral
(DAA) drugs have transformed the treatment of HCV. However, it has become clear that …

Background. We explored the concept of heterologous prime/boost vaccination using 2
therapeutic vaccines currently in clinical development aimed at treating chronically infected …